



# Pharmacy and Therapeutics Committee

May 23, 2019 9:00 AM -5:00 PM  
Gold Room, 3<sup>rd</sup> Floor  
701 E. Jefferson Phoenix, AZ 85034

Teleconference: 1-240-454-0879 Passcode: 807 406 784

## Agenda Topics

9:00 AM

**Welcome and Introductions:** Sara Salek, MD, Chief Medical Officer, AHCCCS

- April 29, 2019 P&T Minutes Review and Vote

9:15 AM

### Supplemental Rebate Class Review:

1. Analgesics, Long Acting Narcotics
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
2. Antibiotics Inhaled
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
3. Anticoagulants
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
4. Antimigraine CRGPs
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony: None
5. Antipsychotics Second Generation Oral
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
6. Antipsychotics Long Acting Atypical Injectables
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
7. COPD Agents
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
8. Cytokine and CAM Antagonists
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
9. Epinephrine – Self-Injected
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:

**“15 MINUTE BREAK”**

10. Glucocorticoids, Inhaled
  - a. Clinical review: Hind Douiki, PharmD- Magellan
  - b. Public Testimony:
  
11. Growth Hormone
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
  
12. Hepatitis C Agents
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
  
13. Hypoglycemics, Incretin Mimetics/Enhancers
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
  
14. Hypoglycemics, Insulin and Related Agents
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
  
15. Opioid Dependence Treatments
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
    - i. Will Humble
    - ii. Michael Dekker
  
16. Pancreatic Enzymes
  - a. Clinical review: Hind Douiki, PharmD - Magellan
  - b. Public Testimony:
  
17. Progestational Agents
  - a. Clinical review: Hind Douiki, PharmD – Magellan
  - b. Public Testimony:
  
18. Stimulants and Related Agents
  - a. Clinical review: Hind Douiki, PharmD – Magellan
  - b. Public Testimony:

**New Drug Reviews: Hind Douiki, PharmD – Magellan**

1. Apadaz: (benzhydrocodone/acetaminophen)
2. Delstrigo: (doravirine/lamivudine/tenofovir disoproxil fumarate)
3. Epidiolex: (cannabidiol)
4. Motegrity: (prucalopride)
5. Pifeltro: (doravirine)
6. Xofluza: (baloxavir marboxil)

<b>12:15 PM</b>	<b>Lunch Break &amp; Executive Session</b>
<b>4:15 PM</b>	<b>Public Therapeutic Class Votes</b>
	<b>Biosimilar Update: None</b>
<b>5:00 PM</b>	<b>Meeting Adjournment</b>

**2019 Meeting Dates:**

- **October 16, 2019**

**2020 Meeting DAtes**

- **January 22, 2020**
- **May 19 & 20, 2020**
- **October 14, 2020**